Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children
- PMID: 2069377
- PMCID: PMC245085
- DOI: 10.1128/AAC.35.4.720
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children
Abstract
The pharmacokinetics of cefetamet were determined after intravenous (i.v.) administration of cefetamet and oral administration of cefetamet pivoxil syrup to patients between the ages of 3 and 12 years. The patients were hospitalized for reconstructive urological surgery; to prevent infection, prophylactic i.v. cefetamet was administered on the day of surgery and oral cefetamet pivoxil was administered 2 days later. After i.v. administration, the mean (+/- standard deviation) half-life of cefetamet was 1.97 +/- 0.60 h (n = 18), which was different from the 2.46 +/- 0.33 h reported for nine adults (22 to 68 years old) in a previous study. The average values for the mean residence times were 2.35 +/- 0.94 and 2.83 +/- 0.34 h and the average values for the fraction of the dose eliminated unchanged in the urine were 79.9% +/- 8.99% and 80% +/- 11% in children and adults, respectively. Plots of mean systemic clearance and steady-state volume of distribution versus body weight for the children and comparative adults were linear on log-log coordinates, and the slopes of the plots were 0.661 and 0.880, respectively. These slope values suggested that mean systemic clearance values per unit of body surface area were similar in children and adults and that maintenance doses for children should be the adult maintenance dose multiplied by the child's surface area divided by 1.73 m2. The mean (+/- standard deviation) oral bioavailabilities of cefetamet pivoxil were 49.3% +/- 15.7% in 3- to 7-year-old children who received a 500-mg dose and 37.9% +/- 10.0% in 8- to 12-year-old children who received a 1,000-mg dose. These values were not different from that observed in the adult group after two 500-mg tablets. Likewise, the peak concentration of cefetamet in plasma and its time of occurrence in children were in line with the values which have been observed for adults.
Similar articles
-
Cefetamet pivoxil clinical pharmacokinetics.Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002. Clin Pharmacokinet. 1993. PMID: 8222459 Review.
-
Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.Antimicrob Agents Chemother. 1990 Jul;34(7):1318-22. doi: 10.1128/AAC.34.7.1318. Antimicrob Agents Chemother. 1990. PMID: 2386364 Free PMC article. Clinical Trial.
-
Influence of maturation and growth on cefetamet pivoxil pharmacokinetics: rational dosing for infants.Antimicrob Agents Chemother. 1996 Mar;40(3):567-74. doi: 10.1128/AAC.40.3.567. Antimicrob Agents Chemother. 1996. PMID: 8851572 Free PMC article. Clinical Trial.
-
Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.Antimicrob Agents Chemother. 1989 Mar;33(3):291-6. doi: 10.1128/AAC.33.3.291. Antimicrob Agents Chemother. 1989. PMID: 2729925 Free PMC article.
-
Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review.Curr Med Res Opin. 1989;11(7):432-41. doi: 10.1185/03007998909115930. Curr Med Res Opin. 1989. PMID: 2673663 Review.
Cited by
-
Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1993 Apr;45(4):589-621. doi: 10.2165/00003495-199345040-00009. Drugs. 1993. PMID: 7684677 Review.
-
Bioavailability of syrup and tablet formulations of cefetamet pivoxil.Antimicrob Agents Chemother. 1993 Dec;37(12):2706-9. doi: 10.1128/AAC.37.12.2706. Antimicrob Agents Chemother. 1993. PMID: 8109939 Free PMC article. Clinical Trial.
-
Formulation development and rheological studies of palatable cefetamet pivoxil hydrochloride dry powder suspension.Daru. 2011;19(2):118-25. Daru. 2011. PMID: 22615648 Free PMC article.
-
Cefetamet pivoxil clinical pharmacokinetics.Clin Pharmacokinet. 1993 Sep;25(3):172-88. doi: 10.2165/00003088-199325030-00002. Clin Pharmacokinet. 1993. PMID: 8222459 Review.
-
A General Biphasic Bodyweight Model for Scaling Basal Metabolic Rate, Glomerular Filtration Rate, and Drug Clearance from Birth to Adulthood.AAPS J. 2022 May 10;24(3):67. doi: 10.1208/s12248-022-00716-y. AAPS J. 2022. PMID: 35538161
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources